Securities Code: 300110
Securities Abbreviation: Huaren Pharmaceutical
Announcement Number: 2026-030
Huaren Pharmaceutical Co., Ltd.
Announcement on the Progress of Major Litigation
The Company and the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Key Information Prompt:
-
Litigation Stage: The court has accepted the case and has not yet commenced trial.
-
Party Status of the Company and its Subsidiaries: The Company and its wholly-owned subsidiary Xi'an Qujiang Huaren Pharmaceutical Co., Ltd. are defendants, and its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. is a third party.
-
Amount Involved: RMB 284,288,000.
-
Impact on the Company's Profit and Loss: The litigation mentioned in this announcement is being retried by the Xi'an Intermediate People's Court under the instruction of the Shaanxi Provincial Higher People's Court, the second instance court. The case has not yet been opened for trial, and the final trial result is still uncertain, making it impossible to determine the impact on the company's current or future profits.
Huaren Pharmaceutical Co., Ltd. (hereinafter referred to as "Huaren Pharmaceutical" or "the Company"), its wholly-owned subsidiary Xi'an Qujiang Huaren Pharmaceutical Co., Ltd. (hereinafter referred to as "Qujiang Huaren"), and its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Hengxing") recently received a summons (Case Number: (2026) Shaan 01 Min Chu 208) and a civil complaint from the Xi'an Intermediate People's Court. The details are announced as follows:
I. Basic Situation of This Litigation